Pasithea Therapeutics
KTTA
8 hedge funds and large institutions have $94.7K invested in Pasithea Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.
0.01% more ownership
Funds ownership: 0.05% → 0.06% (+0.01%)
22% less capital invested
Capital invested by funds: $122K → $94.7K (-$27.2K)
33% less funds holding
Funds holding: 12 → 8 (-4)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$17.5K |
| 2 |
Jane Street
New York
|
+$8.74K |
| 3 |
Renaissance Technologies
New York
|
+$608 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.5K |
| 2 |
VF
Virtu Financial
New York
|
-$7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.14K |
| 4 |
NGA
Naples Global Advisors
Naples,
Florida
|
-$5.09K |
| 5 |
MSFP
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
|
-$1.59K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $48.8K | – | – | – |
|
|
2
Northern Trust
Chicago,
Illinois
| $17.4K | +$17.5K | +2,354 | New |
|
|
3
Renaissance Technologies
New York
| $12K | +$608 | +82 | +5% |
|
|
4
Jane Street
New York
| $8.73K | +$8.74K | +1,179 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.59K | -$37 | -5 | -0.8% |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
7
JP Morgan Chase
New York
| $1.11K | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $47 | -$15 | -2 | -25% |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$18.5K | -1,928 | Closed |
|
|
VF
10
Virtu Financial
New York
| – | -$7K | -773 | Closed |
|
|
XT
11
XTX Topco
George Town,
Cayman Islands
| – | -$5.14K | -536 | Closed |
|
|
NGA
12
Naples Global Advisors
Naples,
Florida
| – | -$5.09K | -531 | Closed |
|
|
MSFP
13
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
| – | -$1.59K | -166 | Closed |
|
14
UBS Group
Zurich,
Switzerland
| – | -$40 | -4 | Closed |
|
KTTA Hedge Fund Activity: Q4 2023 in Review
8 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2023, worth a combined $94.7K — down 22% from $122K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KTTA and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Northern Trust, opening a new position worth an estimated $17.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $18.5K sold.
- 8 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2023, down from 12 in Q3 2023.
- Funds reported $94.7K of Pasithea Therapeutics stock for Q4 2023, down 22% quarter-over-quarter.
- 2 funds opened new Pasithea Therapeutics positions in Q4 2023 and 6 closed out, a net change of -4 holders.
- The largest Pasithea Therapeutics buyer in Q4 2023 was Northern Trust, an estimated $17.5K added.
- The largest Pasithea Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $18.5K sold.
Based on aggregated 13F filings for Q4 2023.